Table 1 Demographics by disease progression in a national, representative cohort of referred patients with chronic kidney disease
Demographics | Progressors N = 2,924 (33.3%) | Non-progressors N = 5,847 (66.6%) |
|---|---|---|
Age, median | 69.9 (59.3–78.7) | 73.4 (64.2–80.6) |
<65 years | 1,091 (37.3%) | 1,568 (26.8%) |
65- < 75 years | 767 (26.2%) | 1,683 (28.8%) |
≥75 years | 1,066 (36.5%) | 2,596 (44.4%) |
Men | 1,931 (66.0%) | 3,670 (62.8%) |
Primary renal disease | ||
Hypertension/renovascular | 732 (25.0%) | 1,538 (26.3%) |
Diabetes nephropathy | 721 (24.7%) | 1,071 (18.3%) |
Glomerulonephritis | 315 (10.8%) | 600 (10.3%) |
Other specified disease | 618 (21.1%) | 1,199 (20.5%) |
Unknown | 538 (18.4%) | 1,439 (24.6%) |
Progression rate (% decline in ml/min/1.73 m2 per year) | −31.9 (−43.9––24.5) | 0.60 (−8.8–14.6) |
Progression rate (absolute change in ml/min/1.73 m2 per year) | −6.1 (−8.6––4.3) | 0.13 (−1.8–3.0) |
Chronic Kidney Disease Stage | ||
G3b | 56 (1.9%) | 1,434 (24.5%) |
G4 | 1,117 (38.2%) | 3,570 (61.1%) |
G5 | 1,751 (59.9%) | 843 (14.4%) |
Comorbidity at baseline | ||
Diabetes | 1,172 (40.1%) | 2,118 (36.2%) |
Cardiovascular disease | 1,109 (37.9%) | 2,205 (37.7%) |
Dementia | 24 (0.8%) | 57 (1.0%) |
Chronic pulmonary disease | 217 (7.4%) | 483 (8.3%) |
Cancer | 414 (14.2%) | 1,011 (17.3%) |
Charlson score above kidney disease median (IQR) | 1.0 (0.00–2.0) | 1.0 (0.0–2.0) |
Current medication | ||
ESA use [n = 7221] | 680 (23.3%) | 1,062 (18.2%) |
Antihypertensives number of, median (IQR) | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) |
Protein restricted diet use | 436 (14.9%) | 545 (9.3%) |
Diuretics use | 2,148 (73.5%) | 3,974 (68.0%) |
Statin use | 1,311 (44.8%) | 2,727 (46.6%) |
Vitamin-D supplements use | 1,770 (60.5%) | 3,005 (51.4%) |
Iron use | ||
intravenous | 286 (9.8%) | 425 (7.3%) |
oral | 524 (17.9%) | 853 (14.6%) |
Laboratory data | ||
P-Albumin (g/l): [n = 8177] | 36.0 (33.0–39.0) | 37.0 (35.0–40.00=) |
S-Calcium (mmol/l): [n = 7578] | 2.28 (2.17–2.37) | 2.31 (2.23–2.39) |
CRP (mmol/l): [n = 5723] | 5.0 (2.8–10.0) | 5.0 (2.5–10.0) |
P-Phosphate (mmol/l): [n = 7997] | 1.5 (1.3–1.8) | 1.2 (1.1–1.4) |
S-Creatinine (mmol/l): | 355 (272–475) | 217 (177–268) |
B-Hemoglobin (g/l): [n = 8537] | 117 (108–127) | 125 (116–135) |
S-PTH (ng/ml): [n = 5818] | 21.0 (12.9–33.7)) | 14.2 (9.5–21.8) |
U-Albumin/creatinine ratio (mg/mmol) [n = 3149] | 40.1 (9.4–170.9) | 12.0 (2.5–48.0) |
eGFR (ml/min/1.73 m2): | 13.3 (9.4–18.2) | 23.6 (18.0–29.9) |
Clinical information | ||
Mean arterial pressure (median mmHg, IQR) [n = 8159] | 97.6 (90.0–106.6) | 96.0 (88.3–103.3) |
Pulse pressure (median mmHg, IQR) [n = 8159] | 60.0 (50.0–75.0) | 60.0 (49.0–70.0) |
BMI (IQR) [n = 6432] | ||
<18.5 Kg/m2 | 27 (0.9%) | 61 (1.0%) |
18.5–25 Kg/m2 | 733 (25.1%) | 1,344 (23.0%) |
25–30 Kg/m2 | 781 (26.7%) | 1,630 (27.9%) |
>30 Kg/m2 | 640 (21.9%) | 1,216 (20.8%) |
Region | ||
Lower North | 676 (23.1%) | 1,319 (22.6%) |
South | 405 (13.9%) | 777 (13.3%) |
Southeast | 356 (12.2%) | 600 (10.3%) |
Southwest | 514 (17.6%) | 1,166 (19.9%) |
Upper North | 151 (5.2%) | 269 (4.6%) |
Stockholm | 822 (28.1%) | 1,716 (29.4%) |
University Hospital | 1,192 (40.8%) | 2,381 (40.7%) |